Sotera Health (NASDAQ: SHC) insider transactions
In the twelve months to 10 November 2026, executives and directors of Sotera Health reported 15 open-market sales of 118,905,720 shares ($1,843m) and 0 open-market purchases, by 10 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 17 August 2026 | Petras Michael B. Jr. | Executive Chairman | Open-market sale | −294,515 | $18.50 | 397,912 | Form 4 |
| 17 August 2026 | Petras Michael B. Jr. | Executive Chairman | Open-market sale | −850,000 | $18.50 | 3,969,393 | Form 4 |
| 7 August 2026 | Rutz Michael P | President of Sterigenics | Open-market sale | −150,000 | $18.84 | 334,279 | Form 4 |
| 5 August 2026 | Lyons Jonathan M. | Sr. Vice President, CFO | Shares withheld for tax | −11,316 | $17.98 | 217,304 | Form 4 |
| 26 May 2026 | Shader Alton | Chief Executive Officer | Grant or award | +375,939 | — | 375,939 | Form 4 |
| 26 May 2026 | Shader Alton | Chief Executive Officer | Grant or award | +203,634 | — | 579,573 | Form 4 |
| 22 May 2026 | Wheadon David E. | Director | Grant or award | +14,970 | — | 89,882 | Form 4 |
| 22 May 2026 | Simon, Christopher | Director | Grant or award | +14,970 | — | 34,102 | Form 4 |
| 22 May 2026 | Chen Ruoxi | Director | Grant or award | +14,970 | — | 95,751 | Form 4 |
| 22 May 2026 | Petrella Vincent K | Director | Grant or award | +14,970 | — | 95,751 | Form 4 |
| 22 May 2026 | Neary James | Director | Grant or award | +14,970 | — | 95,751 | Form 4 |
| 22 May 2026 | Flynn Karen | Director | Grant or award | +14,970 | — | 54,191 | Form 4 |
| 22 May 2026 | Cunningham Sean Laurence | Director | Grant or award | +14,970 | — | 95,751 | Form 4 |
| 22 May 2026 | Krause Kenneth D. | Director | Grant or award | +14,970 | — | 14,970 | Form 4 |
| 22 May 2026 | Kyle Richard G | Director | Grant or award | +14,970 | — | 14,970 | Form 4 |
| 22 May 2026 | Klee Ann R. | Director | Grant or award | +14,970 | — | 140,926 | Form 4 |
| 13 May 2026 | Gtcr Fund Xi/c LP | Director | Open-market sale | −12,735,301 | $15.17 | 0 | Form 4 |
| 13 May 2026 | Warburg Pincus XI, L.P. | Director | Open-market sale | −19,102,952 | $15.17 | 0 | Form 4 |
| 13 May 2026 | Warburg Pincus (Cayman) XI, L.P. | Director | Open-market sale | −19,102,952 | $15.17 | 0 | Form 4 |
| 31 March 2026 | Dimitrief Alexander | Former SVP, GC and Sec. | Shares withheld for tax | −7,941 | $14.34 | 312,040 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Sotera Health page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.